The Oxford COVID-19 vaccine is 'progressing very well,' according to the lead scientists, who said 10,000 more people will be inoculated

Wikimedia Commons

• The head of the Oxford Vaccine Group said Friday that clinic trials on its vaccine for the coronavirus are "progressing very well." 
• 1,000 people have already been inoculated. The next stage will see 10,000 more given the treatment through May and June, Andrew Pollard said.
• The trial vaccine is called as AZD1222 or ChAdOx1 nCoV-19. It was first tested on humans on April 23, following success in macaque monkeys.
• The group said they hoped for clinical test results in two months, but that it could take as long as six. 
• Visit Business Insider's homepage for more stories.

The head of the Oxford Vaccine Group said Friday that its clinical trials are "progressing very well" and that the program will inoculate 10,000 new people.

"We are now initiating studies to evaluate how well the vaccine induces immune responses in older adults," Professor Andrew Pollard, head of the Oxford Vaccine Group, said in a press release.

See the rest of the story at Business Insider

NOW WATCH: How the Navy's largest hospital ship can help with the coronavirus

See Also:

• Skeptical experts in Sweden say its decision to have no lockdown is a terrible mistake that no other nation should copy
• Russian medics are being punished for speaking out against PPE shortages even as thousands of new coronavirus cases are reported daily
• Global coronavirus infections have surpassed 5 million, with almost a third recorded in the US

from Feedburner https://ift.tt/3bPaOd7